Anthracycline-based antibody drug conjugates having high in vivo tolerability
US12121527B2 · kind B2 · utility
0Cited by
21References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 10, 2020 |
| Grant date | Oct 22, 2024 |
| Priority date | — |
| Expiry date | May 5, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/55
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antibody drug conjugates (ADCs) presenting improved properties of in vivo tolerability.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.